COMMUNIQUÉS West-GlobeNewswire

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
09/02/2024
– BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a Humanitarian Aid Program to treat wartime trauma injuries in Ukraine – – The HAV had higher rates of [...]
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
09/02/2024
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines [...]
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
09/02/2024
SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI [...]
Coloplast Finance B.V. - Interim Financial Report, Q1 2023/24
09/02/2024
Q1 2023/24 Interim financial results, Q1 2023/24 1 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin 1) of 28%. Reported revenue in DKK grew 8% with 4%-points [...]
Inteleos Announces 2024 Board of Directors
09/02/2024
Board Brings Extensive Experience Across Healthcare To Support Inteleos’ Mission ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, today announced its [...]
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
09/02/2024
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need The initial trial of OK-101 [...]
Vistin Pharma ASA: Invitation to Q4 2023 conference call
09/02/2024
Oslo, Norway, 9 February 2024 Vistin Pharma ASA will release its fourth quarter and preliminary 2023 results on Friday 16 th of February 2024. Vistin Pharma will host a conference call for all shareholders and [...]
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S
09/02/2024
An extraordinary shareholders’ meeting of Novozymes A/S will be held on Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark. Attachments 2024_09_EGM_Invitation Notice convening the [...]
Invitation to presentation of Mendus’ year-end report for 2023
09/02/2024
Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2023 on Wednesday 14 February 2024 at 08:00 CET. The company will hold a conference call and an online presentation on the same day at 10:00 CET. [...]
Coloplast launches Peristeen® Light for people with bowel disorders
09/02/2024
The new transanal irrigation device is designed to help people facing defecation issues or stool leakage. It is estimated that 10-15% of the world’s population are affected by chronic constipation 1 and that 6% struggle [...]
Coloplast A/S - Interim Financial Report, Q1 2023/24
09/02/2024
Q1 2023/24 Interim financial results, Q1 2023/24 1 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin 1) of 28%. Reported revenue in DKK grew 8% with 4%-points [...]
KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share
09/02/2024
EINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people [...]
IBA acquires Radcal Corporation to expand Medical Imaging Quality Assurance offering and strengthen US presence
09/02/2024
Highly complementary acquisition continues IBA’s expansion strategy to lead the Radiotherapy, Medical Imaging Dosimetry and Quality Assurance markets globally Louvain-la-Neuve, Belgium, February 9, 2024 – IBA (Ion Beam [...]
IBA acquiert Radcal Corporation afin d’élargir son offre d'assurance qualité en imagerie médicale et renforcer sa présence aux États-Unis.
09/02/2024
Acquisition complémentaire en vue de poursuivre la stratégie d'expansion d’IBA pour devenir le leader mondial du marché de l’assurance qualité en radiothérapie et en imagerie médicale. Louvain-la-Neuve, Belgique, le 9 [...]
Metagenomi Announces Pricing of Initial Public Offering
09/02/2024
EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (“Metagenomi”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary [...]
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
08/02/2024
AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and [...]
Telomir Pharmaceuticals Announces Pricing of Initial Public Offering
08/02/2024
BALTIMORE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, is developing Telomir-1 as the first [...]
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
08/02/2024
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and [...]
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/02/2024
EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the [...]

Pages